<p><strong>中生北控生物科技</strong> (HKG:8247) 的股票在过去一个月继续保持其近期的势头，涨幅达到了 56%。过去 30 天的表现是该股票在过去一年中 803% 涨幅的锦上添花，实在是令人瞩目。</p>
<p>即使在如此大幅的价格上涨之后，中生北控生物科技目前仍可能被视为一个强劲的买入机会，其市销率（&#34;P/S&#34;）为 3.2 倍，考虑到香港生物科技行业中几乎一半的公司市销率超过 14.2 倍，甚至市销率高达 71 倍的情况也并不罕见。然而，市销率可能较低是有原因的，需要进一步调查以确定其合理性。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
<p>查看我们对中生北控生物科技的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26051622-ps-multiple-vs-industry-1-dark-2/1771280731031?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26051622-ps-multiple-vs-industry-1-dark-2/1771280731031"/></p>
<p>SEHK:8247 市销率与行业比较 2026 年 2 月 16 日</p>
<h3>中生北控生物科技近期表现如何？</h3>
<p>例如，中生北控生物科技近期收入的下降值得深思。或许市场认为近期的收入表现不足以跟上行业的步伐，导致市销率受到影响。如果你喜欢这家公司，你会希望情况不是这样，以便在它不受欢迎时能够买入一些股票。</p>
<p>想要了解公司收益、收入和现金流的全貌吗？那么我们对中生北控生物科技的 <strong>免费</strong> 报告将帮助你揭示其历史表现。</p>
<h2>收入增长指标告诉我们关于低市销率的什么？</h2>
<p>为了证明其市销率的合理性，中生北控生物科技需要实现远低于行业水平的微弱增长。</p>
<p>回顾一下，公司的去年收入增长并不令人兴奋，出现了令人失望的 21% 的下降。这意味着在更长的时间内，它的收入也出现了下滑，过去三年总收入下降了 35%。因此，不幸的是，我们必须承认该公司在这段时间内未能有效地增长收入。</p>
<p>与公司相比，行业其他部分预计在明年将增长 650%，这确实让公司的近期中期收入下降显得更加突出。</p>
<p>有了这些信息，我们并不感到惊讶中生北控生物科技的市销率低于行业水平。然而，随着收入的下滑，市销率是否已经触底并没有保证。如果公司不改善其收入增长，市销率可能会进一步下降。</p>
<h2>关键要点</h2>
<p>中生北控生物科技的股票已经显著上涨，但其市销率仍然低迷。一般来说，我们倾向于将市销率的使用限制在评估市场对公司整体健康状况的看法。</p>
<p>正如我们所怀疑的，我们对中生北控生物科技的审查显示，其中期收入的萎缩正在导致其低市销率，考虑到行业即将增长。在这个阶段，投资者认为收入改善的潜力不足以证明更高的市销率。除非近期的中期条件改善，否则它们将继续对股价形成障碍。</p>
<p>此外，你还应该了解我们发现的 <strong>中生北控生物科技的一个警示信号</strong>。</p>
<p>如果这些 <strong>风险让你重新考虑对中生北控生物科技的看法</strong>，请查看我们的高质量股票互动列表，以了解还有哪些其他选择。</p>
<h3>估值是复杂的，但我们在这里为你简化。</h3>
<p>通过我们的详细分析，发现中生北控生物科技是否可能被低估或高估，分析内容包括 <strong>公允价值估计、潜在风险、股息、内部交易及其财务状况。</strong></p>
<p>获取免费分析</p>

中生北控生物科技

<p>中生北控生物科技（HKG:8247）股票在过去一个月上涨了 56%，使得过去一年总涨幅达到了令人瞩目的 803%。尽管如此，该公司的低市销率（P/S）为 3.2 倍引发了人们的担忧，因为其收入出现了下降，去年下降了 21%，三年来下降了 35%。生物科技行业预计明年将增长 650%，这突显了中生北控的困境。投资者仍然保持谨慎，因为低市销率反映了对未来收入增长的怀疑，可能限制了股价的上涨，除非业绩有所改善</p>

<p><strong>Biosino Bio-Technology and Science Incorporation</strong> (HKG:8247) shares have continued their recent momentum with a 56% gain in the last month alone. The last 30 days were the cherry on top of the stock's 803% gain in the last year, which is nothing short of spectacular.</p>
<div class="lb-trans"><p><strong>中生北控生物科技</strong> (HKG:8247) 的股票在过去一个月继续保持其近期的势头，涨幅达到了 56%。过去 30 天的表现是该股票在过去一年中 803% 涨幅的锦上添花，实在是令人瞩目。</p>
</div><p>Even after such a large jump in price, Biosino Bio-Technology and Science Incorporation may still look like a strong buying opportunity at present with its price-to-sales (or &#34;P/S&#34;) ratio of 3.2x, considering almost half of all companies in the Biotechs industry in Hong Kong have P/S ratios greater than 14.2x and even P/S higher than 71x aren't out of the ordinary. However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>即使在如此大幅的价格上涨之后，中生北控生物科技目前仍可能被视为一个强劲的买入机会，其市销率（&#34;P/S&#34;）为 3.2 倍，考虑到香港生物科技行业中几乎一半的公司市销率超过 14.2 倍，甚至市销率高达 71 倍的情况也并不罕见。然而，市销率可能较低是有原因的，需要进一步调查以确定其合理性。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
</div><p>View our latest analysis for Biosino Bio-Technology and Science Incorporation</p>
<div class="lb-trans"><p>查看我们对中生北控生物科技的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26051622-ps-multiple-vs-industry-1-dark-2/1771280731031" alt="" original-src="https://images.simplywall.st/asset/chart/26051622-ps-multiple-vs-industry-1-dark-2/1771280731031"/></p>
<p>SEHK:8247 Price to Sales Ratio vs Industry February 16th 2026</p>
<div class="lb-trans"><p>SEHK:8247 市销率与行业比较 2026 年 2 月 16 日</p>
</div><h3>What Does Biosino Bio-Technology and Science Incorporation's Recent Performance Look Like?</h3>
<div class="lb-trans"><h3>中生北控生物科技近期表现如何？</h3>
</div><p>For instance, Biosino Bio-Technology and Science Incorporation's receding revenue in recent times would have to be some food for thought. Perhaps the market believes the recent revenue performance isn't good enough to keep up the industry, causing the P/S ratio to suffer. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>例如，中生北控生物科技近期收入的下降值得深思。或许市场认为近期的收入表现不足以跟上行业的步伐，导致市销率受到影响。如果你喜欢这家公司，你会希望情况不是这样，以便在它不受欢迎时能够买入一些股票。</p>
</div><p>Want the full picture on earnings, revenue and cash flow for the company? Then our <strong>free</strong> report on Biosino Bio-Technology and Science Incorporation will help you shine a light on its historical performance.</p>
<div class="lb-trans"><p>想要了解公司收益、收入和现金流的全貌吗？那么我们对中生北控生物科技的 <strong>免费</strong> 报告将帮助你揭示其历史表现。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The Low P/S?</h2>
<div class="lb-trans"><h2>收入增长指标告诉我们关于低市销率的什么？</h2>
</div><p>In order to justify its P/S ratio, Biosino Bio-Technology and Science Incorporation would need to produce anemic growth that's substantially trailing the industry.</p>
<div class="lb-trans"><p>为了证明其市销率的合理性，中生北控生物科技需要实现远低于行业水平的微弱增长。</p>
</div><p>Taking a look back first, the company's revenue growth last year wasn't something to get excited about as it posted a disappointing decline of 21%. This means it has also seen a slide in revenue over the longer-term as revenue is down 35% in total over the last three years. So unfortunately, we have to acknowledge that the company has not done a great job of growing revenue over that time.</p>
<div class="lb-trans"><p>回顾一下，公司的去年收入增长并不令人兴奋，出现了令人失望的 21% 的下降。这意味着在更长的时间内，它的收入也出现了下滑，过去三年总收入下降了 35%。因此，不幸的是，我们必须承认该公司在这段时间内未能有效地增长收入。</p>
</div><p>In contrast to the company, the rest of the industry is expected to grow by 650% over the next year, which really puts the company's recent medium-term revenue decline into perspective.</p>
<div class="lb-trans"><p>与公司相比，行业其他部分预计在明年将增长 650%，这确实让公司的近期中期收入下降显得更加突出。</p>
</div><p>With this information, we are not surprised that Biosino Bio-Technology and Science Incorporation is trading at a P/S lower than the industry. Nonetheless, there's no guarantee the P/S has reached a floor yet with revenue going in reverse. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.</p>
<div class="lb-trans"><p>有了这些信息，我们并不感到惊讶中生北控生物科技的市销率低于行业水平。然而，随着收入的下滑，市销率是否已经触底并没有保证。如果公司不改善其收入增长，市销率可能会进一步下降。</p>
</div><h2>The Key Takeaway</h2>
<div class="lb-trans"><h2>关键要点</h2>
</div><p>Shares in Biosino Bio-Technology and Science Incorporation have risen appreciably however, its P/S is still subdued. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.</p>
<div class="lb-trans"><p>中生北控生物科技的股票已经显著上涨，但其市销率仍然低迷。一般来说，我们倾向于将市销率的使用限制在评估市场对公司整体健康状况的看法。</p>
</div><p>As we suspected, our examination of Biosino Bio-Technology and Science Incorporation revealed its shrinking revenue over the medium-term is contributing to its low P/S, given the industry is set to grow. At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio. Unless the recent medium-term conditions improve, they will continue to form a barrier for the share price around these levels.</p>
<div class="lb-trans"><p>正如我们所怀疑的，我们对中生北控生物科技的审查显示，其中期收入的萎缩正在导致其低市销率，考虑到行业即将增长。在这个阶段，投资者认为收入改善的潜力不足以证明更高的市销率。除非近期的中期条件改善，否则它们将继续对股价形成障碍。</p>
</div><p>Plus, you should also learn about this <strong>1 warning sign we've spotted with Biosino Bio-Technology and Science Incorporation</strong>.</p>
<div class="lb-trans"><p>此外，你还应该了解我们发现的 <strong>中生北控生物科技的一个警示信号</strong>。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on Biosino Bio-Technology and Science Incorporation</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果这些 <strong>风险让你重新考虑对中生北控生物科技的看法</strong>，请查看我们的高质量股票互动列表，以了解还有哪些其他选择。</p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值是复杂的，但我们在这里为你简化。</h3>
</div><p>Discover if Biosino Bio-Technology and Science Incorporation might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通过我们的详细分析，发现中生北控生物科技是否可能被低估或高估，分析内容包括 <strong>公允价值估计、潜在风险、股息、内部交易及其财务状况。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>获取免费分析</p>
</div>

中生北控生物科技（HKG:8247）即便股价已上涨 56%，仍因增长乏力而受到制约